| Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury. | |
| | |
MedLine Citation:
|
PMID: 16960983 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Synthetic high density lipoproteins (sHDL) are discoidal lipoprotein particles made of an apolipoprotein and a phospholipid, which mimic most, if not all, of the atheroprotective properties of plasma HDL, including stimulation of reverse cholesterol transport (RCT), prevention of endothelial dysfunction, and inhibition of lipid oxidation. sHDL are currently under development as a novel treatment for atherosclerotic cardiovascular disease. A number of preclinical studies have demonstrated the ability of single or multiple injections of sHDL to induce the regression of atherosclerotic plaques and prevent arterial restenosis. In the first phase II trial in patients with acute coronary syndromes, a short-term treatment with sHDL containing the disulfide-linked dimer of the apolipoprotein A-IMilano variant (A-IM/A-IM) caused a remarkable reduction of atheroma volume. sHDL also display a direct cardioprotective activity in ex vivo and in vivo models of myocardial ischemia/reperfusion (I/R) injury, and may become a useful adjunctive therapy to improve clinical outcomes in patients with acute coronary syndromes or undergoing coronary procedures. |
| | |
Authors:
|
- |
Related Documents
:
|
834123 - Maximum lipid reduction by partial ileal bypass: a test of the lipid-atherosclerosis hy... 7503003 - Noninvasive tracking of coronary atherosclerosis by electron beam computed tomography: ... 2953553 - Early and late results of coronary bypass surgery. evolution and the influence of cardi... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Pharmacology & therapeutics Volume: 111 ISSN: 0163-7258 ISO Abbreviation: Pharmacol. Ther. Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-09-07 Completed Date: 2006-12-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7905840 Medline TA: Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 836-54 Citation Subset: IM |
Affiliation:
|
Center E. Grossi Paoletti, Department of Pharmacological Sciences, Milano, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antioxidants / pharmacology Apolipoprotein A-I / blood Atherosclerosis / prevention & control Cholesterol / metabolism Endothelium, Vascular / drug effects, physiology Humans Lipoproteins, HDL / blood, pharmacology, physiology, therapeutic use* Lipoproteins, LDL / metabolism Myocardial Reperfusion Injury / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antioxidants; 0/Apolipoprotein A-I; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 5-hydroxytryptamine receptors in the human cardiovascular system.
Next Document: Introduction to the newborn screening fact sheets.